Cantor Fitzgerald Reaffirms Overweight Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)

Key Points

• Cantor Fitzgerald reaffirmed its “Overweight” rating on BioMarin Pharmaceutical and maintained an $86 price target, implying approximately 57% upside from the stock’s $54.67 price.
• Analyst sentiment remains broadly positive, with the company carrying a consensus “Moderate Buy” rating and an average price target of $88.75; targets range from $62 to $114.
• BioMarin exceeded quarterly expectations, reporting $1.20 in earnings per share versus the $0.95 consensus and $989.71 million in revenue, up 20% year over year. Institutional investors own approximately 98.71% of the company’s shares.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $86.00 target price on the biotechnology company's stock. Cantor Fitzgerald's price target suggests a potential upside of 57.31% from the company's current price.

Other equities analysts have also recently issued reports about the stock. Citigroup lifted their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Raymond James Financial raised shares of BioMarin Pharmaceutical from an "outperform" rating to a "strong-buy" rating and set a $109.00 price target on the stock in a research report on Monday, October 12th. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Royal Bank Of Canada reduced their price target on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating on the stock in a research report on Tuesday, July 7th. Finally, Jefferies Financial Group lifted their price target on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a "buy" rating in a research report on Monday, August 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $88.75.

BioMarin Pharmaceutical Trading Down 0.0%

Shares of NASDAQ BMRN opened at $54.67 on Tuesday. The company's fifty day moving average is $62.73 and its 200-day moving average is $58.67. The stock has a market cap of $10.58 billion, a price-to-earnings ratio of 147.76, a P/E/G ratio of 0.38 and a beta of 0.22. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to analysts' expectations of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business's quarterly revenue was up 20.0% compared to the same quarter last year. During the same period last year, the firm posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts predict that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of BMRN. Primecap Management Co. CA bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth about $811,962,000. Dimensional Fund Advisors LP lifted its position in BioMarin Pharmaceutical by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company's stock worth $214,804,000 after buying an additional 481,176 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in BioMarin Pharmaceutical by 35.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,920,658 shares of the biotechnology company's stock worth $108,498,000 after buying an additional 501,591 shares in the last quarter. First Trust Advisors LP lifted its position in BioMarin Pharmaceutical by 43.3% during the 1st quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company's stock worth $94,479,000 after buying an additional 505,692 shares in the last quarter. Finally, Caisse de depot et placement du Quebec bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth about $70,749,000. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.